Compare CBLL & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBLL | QTRX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.8M | 352.7M |
| IPO Year | 2024 | 2017 |
| Metric | CBLL | QTRX |
|---|---|---|
| Price | $21.71 | $7.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $25.17 | $10.33 |
| AVG Volume (30 Days) | 596.0K | ★ 867.6K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $82,813,000.00 | ★ $130,203,000.00 |
| Revenue This Year | $37.43 | N/A |
| Revenue Next Year | $27.87 | $28.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.93 | N/A |
| 52 Week Low | $10.01 | $4.05 |
| 52 Week High | $32.75 | $12.41 |
| Indicator | CBLL | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 79.60 | 64.57 |
| Support Level | $19.87 | $7.44 |
| Resistance Level | $24.25 | $7.81 |
| Average True Range (ATR) | 1.10 | 0.40 |
| MACD | 0.31 | -0.01 |
| Stochastic Oscillator | 68.41 | 63.29 |
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.